Fazli L - Search Results

1

Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.

McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD. McKenney JK, et al. Among authors: fazli l. Am J Surg Pathol. 2016 Nov;40(11):1439-1456. doi: 10.1097/PAS.0000000000000736. Am J Surg Pathol. 2016. PMID: 27635949

2

Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME. July LV, et al. Among authors: fazli l. Mol Cancer Ther. 2004 Mar;3(3):223-32. Mol Cancer Ther. 2004. PMID: 15026542

3

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Rocchi P, et al. Among authors: fazli l. Cancer Res. 2004 Sep 15;64(18):6595-602. doi: 10.1158/0008-5472.CAN-03-3998. Cancer Res. 2004. PMID: 15374973

4

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.

Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME. Krueckl SL, et al. Among authors: fazli l. Cancer Res. 2004 Dec 1;64(23):8620-9. doi: 10.1158/0008-5472.CAN-04-2446. Cancer Res. 2004. PMID: 15574769

5

Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.

Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Knudsen BS, et al. Among authors: fazli l. Am J Pathol. 2005 Jul;167(1):255-66. doi: 10.1016/S0002-9440(10)62970-7. Am J Pathol. 2005. PMID: 15972969 Free PMC article.

6

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. Chi KN, et al. Among authors: fazli l. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. doi: 10.1093/jnci/dji252. J Natl Cancer Inst. 2005. PMID: 16145049 Clinical Trial.

7

Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer.

Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, Rennie PS. Ray MR, et al. Among authors: fazli l. Int J Cancer. 2006 Mar 1;118(5):1108-19. doi: 10.1002/ijc.21469. Int J Cancer. 2006. PMID: 16161052 Free article.

8

A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.

Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME. Yamanaka K, et al. Among authors: fazli l. Mol Cancer Ther. 2005 Nov;4(11):1689-98. doi: 10.1158/1535-7163.MCT-05-0064. Mol Cancer Ther. 2005. PMID: 16275990

9

Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.

Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M. Rocchi P, et al. Among authors: fazli l. Cancer Res. 2005 Dec 1;65(23):11083-93. doi: 10.1158/0008-5472.CAN-05-1840. Cancer Res. 2005. PMID: 16322258

10

Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.

So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. So A, et al. Among authors: fazli l. Mol Cancer Ther. 2005 Dec;4(12):1837-49. doi: 10.1158/1535-7163.MCT-05-0178. Mol Cancer Ther. 2005. PMID: 16373699

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

267 results

Search Page